TY  - JOUR
T1  - IS what is good for the gander really good for the goose?
AU  - Redberg RF
Y1  - 2009/09/12
N1  - 10.1001/archinternmed.2009.261
JO  - Archives of Internal Medicine
SP  - 1460
EP  - 1461
VL  - 169
IS  - 16
N2  - 
The use of implantable cardioverter- defibrillators (ICDs) has grown rapidly in the last decade. Originally reserved for only the highest-risk patients such as survivors of sudden cardiac death (SCD), use of ICDs has expanded to include primary prevention following the publication of 2 randomized clinical trials establishing their efficacy.1- 2 Since then, the great challenge in ICD use has been to identify those at greatest risk for SCD—that is, the population who would benefit the most from implantation. Cardiologists have used various criteria, such as the width of QRS and T-wave alternans, for risk stratification. Meanwhile, the use of ICDs has expanded even beyond those with heart failure to include younger patients with such conditions as arrhythmogenic right ventricular dysplasia, long QT syndrome, and hypertrophic cardiomyopathy.3

SN  - 0003-9926
M3  - doi: 10.1001/archinternmed.2009.261
UR  - http://dx.doi.org/10.1001/archinternmed.2009.261
ER  -